清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

医学 多发性骨髓瘤 总体生存率 肿瘤科 内科学 临床试验 无进展生存期 生存分析 相(物质) 临床研究阶段 梅德林 存活率 人口
作者
Hermann Einsele,J. San‐Miguel,Binod Dhakal,Cyrille Touzeau,Xavier P Leleu,Niels W.C.J. van de Donk,Surbhi Sidana,Albert Oriol,Yael Chava Cohen,Simon James Harrison,María‐Victoria Mateos,Martínez-López Joaquín,Paolo Corradini,Lionel Karlin,Diana Chen,Quanlin Li,Tzu-min Yeh,Katherine Li,Vicki Plaks,Ana Slaughter
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:27 (2): 254-268 被引量:69
标识
DOI:10.1016/s1470-2045(25)00653-9
摘要

Background In CARTITUDE-4, a single infusion of ciltacabtagene autoleucel (cilta-cel) significantly prolonged progression-free survival in patients with lenalidomide-refractory multiple myeloma. We report updated overall survival and longer-term efficacy and safety outcomes. Methods CARTITUDE-4 is an open-label, multicentre, randomised, phase 3 trial at 81 hospital sites in the USA, Europe, Asia, and Australia. Eligible patients were adults (aged >18 years) with lenalidomide-refractory multiple myeloma, with one to three previous treatment lines, including a proteasome inhibitor and an immunomodulatory drug, and an Eastern Cooperative Oncology Group performance status of 0 or 1. After the trial started, the threshold defining measurable disease was lowered to 0·5 g/dL from 1·0 g/dL serum monoclonal paraprotein on July 2, 2021, to increase trial access. Patients were randomly assigned (1:1) via a computerised algorithm and balanced with permuted blocks, with stratification by physician's choice of pomalidomide–bortezomib–dexamethasone versus daratumumab–pomalidomide–dexamethasone, International Staging System stage, and number of previous treatment lines. Patients were assigned to cilta-cel (apheresis, bridging therapy [at least one pomalidomide–bortezomib–dexamethasone or daratumumab–pomalidomide–dexamethasone cycle], lymphodepletion, then cilta-cel infusion [0·75 × 10 6 CAR T cells per kg]) or standard of care (pomalidomide–bortezomib–dexamethasone [21-day cycles: 4 mg/day oral pomalidomide on days 1–14; 1·3 mg/m 2 subcutaneous bortezomib twice a week for 2 weeks for eight cycles, then once a week for 2 weeks per cycle; 20 mg or, if aged >75 years, 10 mg oral dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12 for eight cycles, then days 1, 2, 8, and 9 per cycle] or daratumumab–pomalidomide–dexamethasone [28-day cycles: 1800 mg subcutaneous daratumumab weekly for 2 cycles, every 2 weeks for four cycles, then every 4 weeks; 4 mg/day oral pomalidomide on days 1–21; 40 mg/week or, if aged >75 years, 20 mg/week oral or intravenous dexamethasone]). The primary endpoint was progression-free survival, previously published. In this Article, we report a prespecified second interim analysis of overall survival and an updated analysis of progression-free survival in the intention-to-treat population. This trial was registered at ClinicalTrials.gov (NCT04181827) and is ongoing. Findings Patients were randomly assigned between July 10, 2020, and Nov 17, 2021, to receive cilta-cel (n=208) or standard of care (n=211). At a median follow-up of 33·6 months (IQR 20·3–35·0), median progression-free survival was not reached (95% CI 34·5 months–not evaluable) in the cilta-cel group versus 11·8 months (9·7–14·0) in the standard-of-care group (HR 0·29 [95% CI 0·22–0·39]). Median overall survival was not reached (95% CI not evaluable) with cilta-cel versus not reached (37·7 months–not evaluable) with standard of care (HR 0·55 [95% CI 0·39–0·79]; p=0·0009). 30 (14%) of 208 patients in the cilta-cel group and 77 (37%) of 208 in the standard-of-care group had maximum grade 3 treatment-emergent adverse events, most commonly anaemia (72 [35%]) in the cilta-cel group and neutropenia (59 [28%]) in the standard-of-care group. Rates of maximum grade 4 treatment-emergent adverse events were 156 (75%) with cilta-cel and 116 (56%) with standard of care, most commonly neutropenia (152 [73%] with cilta-cel and 112 [54%] with standard of care). Serious treatment-emergent adverse events occurred in 98 (47%) patients in each group. Deaths in the safety population occurred in 50 (24%) in the cilta-cel group and 82 (39%) in the standard-of-care group, including due to treatment-related adverse events in six (3%; four due to infection) in the cilta-cel group and five (2%; all due to infection) in the standard-of-care group. Interpretation The significantly improved overall survival and patient-reported measures in CARTITUDE-4 reinforce the use of cilta-cel in treating relapsed or refractory multiple myeloma as early as after first relapse. Funding Johnson & Johnson, Legend Biotech USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
6秒前
ZLPY发布了新的文献求助30
11秒前
顺利的访曼完成签到,获得积分10
30秒前
35秒前
虚心从蓉完成签到,获得积分10
39秒前
麻团儿完成签到,获得积分10
40秒前
40秒前
冷酷冬卉完成签到,获得积分10
47秒前
852的应助被TingtingGZ采纳,获得10
47秒前
54秒前
55秒前
zjkzh完成签到 ,获得积分10
57秒前
TingtingGZ发布了新的文献求助10
1分钟前
眯眯眼的板凳完成签到,获得积分10
1分钟前
星辰大海的应助被TingtingGZ采纳,获得10
1分钟前
隐形曼青的应助被ZLPY采纳,获得10
1分钟前
激情的汲完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
满意野狼完成签到,获得积分10
1分钟前
雪白的魔镜完成签到,获得积分10
1分钟前
2分钟前
Gary完成签到 ,获得积分10
2分钟前
义气的夏旋完成签到,获得积分10
2分钟前
执着可仁完成签到 ,获得积分10
2分钟前
神勇如雪完成签到,获得积分10
2分钟前
DATATA完成签到 ,获得积分10
2分钟前
老实大炮完成签到,获得积分10
2分钟前
酷酷的海莲完成签到,获得积分10
2分钟前
2分钟前
滴滴如玉发布了新的文献求助10
2分钟前
2分钟前
TingtingGZ发布了新的文献求助10
2分钟前
科目三的应助被姜OMG采纳,获得10
2分钟前
2分钟前
369ninja发布了新的文献求助10
2分钟前
懵懂的莺完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173198
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780496
捐赠科研通 7767332
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476688